

# Marco Metra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/809523/publications.pdf>

Version: 2024-02-01

769  
papers

65,417  
citations

1094

112  
h-index

1082

232  
g-index

824  
all docs

824  
docs citations

824  
times ranked

39580  
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
2	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
3	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal, 2006, 28, 230-268.	1.0	1,802
4	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, The, 2003, 362, 7-13.	6.3	1,664
5	Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 2020, 5, 819.	3.0	1,465
6	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	1.2	1,280
7	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
8	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	1.0	1,114
9	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
10	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€”Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	1.2	1,044
11	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484.	1.6	1,031
12	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
13	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, The, 2013, 381, 29-39.	6.3	810
14	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 0.7 661		
15	Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace, 2006, 8, 651-745. EUR<i>Observational</i> Research Programme: regional differences and 1â€”year followâ€”up results of the Heart Failure Pilot Survey (ESCâ€”HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	2.9	645
16	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews, 2020, 19, 102568.	2.5	637
17	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
18	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationâ€”executive summary. European Heart Journal, 2006, 27, 1979-2030.	1.0	612

#	ARTICLE	IF	CITATIONS
19	The use of diuretics in heart failure with congestion " a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	2.9	605
20	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	2.9	593
21	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. European Heart Journal, 2005, 26, 1303-1308.	1.0	564
22	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	2.9	555
23	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq1 1 0.784314 rgbT /Over	0.7	546
24	European Society of Cardiology Heart Failure Long-Term Registry (<sc>ESCâ€HFâ€LT</sc>): 1â€year followâ€up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	2.9	538
25	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	2.9	533
26	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
27	Heart failure. Lancet, The, 2017, 390, 1981-1995.	6.3	483
28	Rolofylline, an Adenosine A<sub>1</sub>-Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine, 2010, 363, 1419-1428.	13.9	473
29	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq1 1 0.784314 rgbT /Over	1.0	454
30	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 433-443.	2.9	449
31	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	2.9	446
32	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal, 2020, 41, 1821-1829.	1.0	434
33	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	6.3	425
34	Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?. Circulation: Heart Failure, 2012, 5, 54-62.	1.6	398
35	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. Journal of the American College of Cardiology, 2013, 61, 196-206.	1.2	397
36	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, The, 2009, 373, 1429-1439.	6.3	387

#	ARTICLE	IF	CITATIONS
37	PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. <i>Circulation</i> , 2000, 102, 636-641.	1.6	384
38	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
39	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
40	EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	2.9	340
41	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	2.9	335
42	Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. <i>European Journal of Heart Failure</i> , 2008, 10, 188-195.	2.9	331
43	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2009.	3.8	330
44	Differential Effects of $\beta$ -Blockers in Patients With Heart Failure. <i>Circulation</i> , 2000, 102, 546-551.	1.6	317
45	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315
46	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
47	Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1678-1687.	1.2	303
48	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation Executive Summary. <i>Circulation</i> , 2006, 114, 700-752.	1.6	294
49	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
50	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	1.0	276
51	Fluid overload in acute heart failure - redistribution and other mechanisms beyond fluid accumulation. <i>European Journal of Heart Failure</i> , 2008, 10, 165-169.	2.9	260
52	Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 11-17.	0.7	255
53	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. <i>Circulation</i> , 2018, 138, 1088-1099.	1.6	253
54	Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. <i>European Heart Journal</i> , 2008, 29, 1644-1652.	1.0	248

#	ARTICLE	IF	CITATIONS
55	Epidemiology, pathophysiology and contemporary management of cardiogenic shock – A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1315-1341.	2.9	244
56	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	6.3	229
57	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
58	Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1248-1258.	1.2	220
59	Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. <i>American Heart Journal</i> , 2010, 159, 841-849.e1.	1.2	214
60	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. <i>Journal of the American College of Cardiology</i> , 2014, 63, 778-785.	1.2	213
61	Evaluation of kidney function throughout the heart failure trajectory – A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 584-603.	2.9	213
62	The role of the kidney in heart failure. <i>European Heart Journal</i> , 2012, 33, 2135-2142.	1.0	209
63	<sc>COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. <i>European Journal of Heart Failure</i> , 2020, 22, 957-966.	2.9	208
64	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. <i>International Journal of Cardiology</i> , 2013, 168, 2186-2194.	0.8	207
65	The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. <i>European Journal of Heart Failure</i> , 2019, 21, 402-424.	2.9	202
66	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. <i>European Heart Journal</i> , 2006, 27, 1440-1446.	1.0	201
67	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
68	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
69	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. <i>International Journal of Cardiology</i> , 2013, 167, 2710-2718.	0.8	183
70	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
71	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
72	Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics. <i>American Journal of Cardiology</i> , 1992, 70, 622-628.	0.7	177

#	ARTICLE	IF	CITATIONS
73	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	13.9	174
74	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	2.9	172
75	Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia. <i>American Heart Journal</i> , 1994, 128, 564-574.	1.2	170
76	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 473-481.	1.6	170
77	Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET. <i>Journal of Cardiac Failure</i> , 2005, 11, 288-292.	0.7	168
78	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	2.9	162
79	The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment. <i>Journal of Cardiac Failure</i> , 2008, 14, 631-640.	0.7	160
80	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	2.9	160
81	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	1.2	159
82	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet</i> , 2019, 394, 1254-1263.	6.3	159
83	Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. <i>European Journal of Heart Failure</i> , 2012, 14, 219-225.	2.9	158
84	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	0.8	157
85	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	2.9	157
86	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. <i>JAMA Cardiology</i> , 2020, 5, 1274.	3.0	157
87	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , 2005, 26, 2259-2268.	1.0	154
88	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1064-1108.	1.2	154
89	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	2.9	154
90	Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1805-1811.	1.2	149

#	ARTICLE	IF	CITATIONS
91	A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149
92	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 2017, 38, ehw543.	1.0	148
93	Adrenomedullin in heart failure: pathophysiology and therapeutic application. European Journal of Heart Failure, 2019, 21, 163-171.	2.9	144
94	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
95	The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. European Journal of Heart Failure, 2007, 9, 776-786.	2.9	139
96	Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 2007, 93, 968-973.	1.2	135
97	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	1.6	134
98	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcomeâ€”an analysis from <scp>RELAXâ€AHF</scp>. European Journal of Heart Failure, 2014, 16, 1230-1240.	2.9	134
99	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
100	Heart failure in elderly patients: distinctive features and unresolved issues. European Journal of Heart Failure, 2013, 15, 717-723.	2.9	130
101	Micronutrient Deficiencies. Journal of the American College of Cardiology, 2009, 54, 1660-1673.	1.2	127
102	Relaxin: Review of Biology and Potential Role in Treating Heart Failure. Current Heart Failure Reports, 2010, 7, 75-82.	1.3	125
103	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. Journal of the American College of Cardiology, 2011, 57, 1899-1907.	1.2	125
104	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123
105	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation, 2018, 137, 1320-1330.	1.6	121
106	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	1.7	118
107	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. Journal of Cardiac Failure, 2016, 22, 182-189.	0.7	118
108	Prevalence, Characteristics, and Outcomes of COVID-19â€Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118

#	ARTICLE	IF	CITATIONS
109	Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1999, 33, 943-950.	1.2	117
110	Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development. <i>Circulation Research</i> , 2003, 93, 414-420.	2.0	117
111	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. <i>European Heart Journal</i> , 2009, 30, 3015-3026.	1.0	117
112	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. <i>European Heart Journal</i> , 2011, 32, 2563-2572.	1.0	116
113	$\beta$ -Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. <i>European Journal of Heart Failure</i> , 2003, 5, 621-627.	2.9	115
114	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
115	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 321-329.	1.7	113
116	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012, 14, 1208-1217.	2.9	112
117	Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. <i>Annals of Thoracic Surgery</i> , 2003, 76, 778-783.	0.7	111
118	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	1.2	111
119	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 "care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
120	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	2.9	110
121	Highlights in heart failure. <i>ESC Heart Failure</i> , 2019, 6, 1105-1127.	1.4	109
122	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	1.6	107
123	A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on Acute decompensated Heart Failure: The LAN-HF Score. <i>Heart</i> , 2014, 100, 115-125.	1.2	106
124	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine - short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
125	Marked improvement in left ventricular ejection fraction during long-term $\beta$ -blockade in patients with chronic heart failure: Clinical correlates and prognostic significance. <i>American Heart Journal</i> , 2003, 145, 292-299.	1.2	104
126	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , 2014, 35, 431-441.	1.0	104



#	ARTICLE	IF	CITATIONS
127	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	2.9	104
128	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	1.6	103
129	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. <i>International Journal of Cardiology</i> , 2016, 222, 303-312.	0.8	103
130	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	1.0	102
131	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
132	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	2.9	100
133	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340.	1.9	100
134	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	2.9	99
135	Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the CardioCOVID-Italy multicentre study. <i>European Journal of Heart Failure</i> , 2020, 22, 2238-2247.	2.9	99
136	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T Cardiology</i> , 2014, 173, 163-169.	0.8	98
137	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
138	The "Ten Commandments"™ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2022, 43, 440-441.	1.0	95
139	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.	2.9	91
140	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	1.0	90
141	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017, 19, 1520-1529.	2.9	89
142	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	2.9	88
143	Task force on. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 757-766.	0.6	88
144	Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health. <i>Nutrients</i> , 2016, 8, 363.	1.7	88

#	ARTICLE	IF	CITATIONS
145	Long-Term Survival of Patients With Heart Failure and Ventricular Conduction Delay Treated With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2007, 99, 232-238.	0.7	87
146	The European CRT Survey: 1 year (9–15 months) follow-up results. <i>European Journal of Heart Failure</i> , 2012, 14, 61-73.	2.9	87
147	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	2.9	86
148	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. <i>European Journal of Heart Failure</i> , 2007, 9, 901-909.	2.9	85
149	Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. <i>Heart Failure Reviews</i> , 2009, 14, 243-253.	1.7	85
150	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
151	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	1.0	84
152	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. <i>European Journal of Heart Failure</i> , 2018, 20, 700-710.	2.9	84
153	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	1.6	82
154	Treatment of functional mitral regurgitation in chronic heart failure: can we get a “proof of concept” from the MITRA-ER and COAPT trials?. <i>European Journal of Heart Failure</i> , 2019, 21, 852-861.	2.9	82
155	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	2.9	81
156	Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. <i>Heart</i> , 2019, 105, heartjnl-2018-314173.	1.2	81
157	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	80
158	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , 2022, 43, 1033-1058.	1.0	80
159	Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1990, 65, 1127-1133.	0.7	79
160	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
161	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	1.9	78
162	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	1.0	78

#	ARTICLE	IF	CITATIONS
163	Congestive Heart Failure Cardiopoietic Regenerative Therapy (<sc>CHART</sc> ) trial design. <i>European Journal of Heart Failure</i> , 2016, 18, 160-168.	2.9	77
164	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. <i>Journal of Cardiac Failure</i> , 2010, 16, 25-35.	0.7	76
165	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713560.	1.1	76
166	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013, 15, 551-559.	2.9	75
167	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1353-1362.	0.3	75
168	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. <i>American Heart Journal</i> , 2005, 149, 370-376.	1.2	74
169	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	1.2	74
170	Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. <i>American Journal of Cardiology</i> , 1991, 68, 1060-1066.	0.7	73
171	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <sc>ENGAGE AF-TIMI</sc> 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161.	2.9	73
172	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	1.2	73
173	Left internal thoracic artery~radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 179-184.	0.4	72
174	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the <sc>PROTECT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71
175	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1795-1807.	1.2	71
176	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
177	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <sc>PROTECT</sc> study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	2.9	70
178	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	2.9	70
179	COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 15-25.	1.1	70
180	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , 2002, 4, 321-329.	2.9	69

#	ARTICLE	IF	CITATIONS
181	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a $\beta$ -blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , 2007, 9, 795-801.	2.9	69
182	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	2.9	69
183	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69
184	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	1.9	68
185	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	2.9	68
186	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005, 150, 46-53.	1.2	67
187	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
188	A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1603-1611.	1.2	66
189	Heart Failure Association of the European Society of Cardiology update on sodium-glucose cotransporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
190	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 179-188.	0.7	65
191	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
192	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group. <i>European Journal of Heart Failure</i> , 2016, 18, 545-553.	2.9	64
193	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 732-743.	2.9	64
194	Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure. <i>American Journal of Cardiology</i> , 2010, 106, 1292-1296.	0.7	63
195	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 624-633.	2.9	63
196	A rationale for the use of $\beta$ -blockers as standard treatment for heart failure. <i>American Heart Journal</i> , 2000, 139, 511-521.	1.2	62
197	Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 963-971.	1.2	62
198	Postdischarge Assessment After a Heart Failure Hospitalization. <i>Circulation</i> , 2010, 122, 1782-1785.	1.6	62

#	ARTICLE	IF	CITATIONS
199	Nutritional Deficiency in Patients with Heart Failure. <i>Nutrients</i> , 2016, 8, 442.	1.7	62
200	Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1003-1023.	0.3	61
201	Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. <i>International Journal of Cardiology</i> , 2010, 144, 175-179.	0.8	61
202	The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 5-15.	1.3	60
203	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	1.2	60
204	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 977-987.	1.6	60
205	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	1.6	60
206	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	2.9	60
207	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , 2019, 21, 208-217.	2.9	60
208	Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. <i>IJC Heart and Vasculature</i> , 2021, 34, 100774.	0.6	60
209	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , 2010, 12, 499-507.	2.9	59
210	Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 49-60.	1.3	59
211	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59
212	Hyponatremia and Long-Term Outcomes in Chronic Heart Failureâ€”An Observational Study From the Duke Databank for Cardiovascular Diseases. <i>Journal of Cardiac Failure</i> , 2012, 18, 74-81.	0.7	58
213	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	1.6	58
214	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
215	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
216	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€”CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57

#	ARTICLE	IF	CITATIONS
217	Clinical Role of CA125 in Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 386-397.	1.9	57
218	Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 603-619.	2.9	57
219	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 76-84.	0.6	56
220	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. <i>Cardiology</i> , 2011, 119, 96-105.	0.6	56
221	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	1.0	56
222	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
223	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. <i>Nutrition</i> , 2015, 31, 72-78.	1.1	56
224	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
225	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	0.8	53
226	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	2.9	53
227	The Safety of Amiodarone in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 340-345.	0.7	52
228	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , 2009, 14, 299-307.	1.7	52
229	Nebivolol. <i>Drugs</i> , 2010, 70, 41-56.	4.9	52
230	Heart failure in the last year: progress and perspective. <i>ESC Heart Failure</i> , 2020, 7, 3505-3530.	1.4	52
231	Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization. <i>American Journal of Cardiology</i> , 1989, 63, 7-13.	0.7	51
232	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	1.7	51
233	Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	1.4	50
234	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50

#	ARTICLE	IF	CITATIONS
235	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	2.9	50
236	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	2.9	49
237	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	1.9	49
238	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	2.9	49
239	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	1.2	48
240	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	1.7	48
241	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	2.9	48
242	Treatment with 24-hour isartoxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1684-1693.	2.9	48
243	Ventilatory Efficiency and the Selection of Patients for Heart Transplantation. <i>Circulation: Heart Failure</i> , 2010, 3, 378-386.	1.6	47
244	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	2.9	47
245	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
246	Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. <i>European Journal of Heart Failure</i> , 2019, 21, 196-204.	2.9	47
247	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
248	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	2.9	47
249	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
250	Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?. <i>Heart Failure Reviews</i> , 2004, 9, 123-130.	1.7	46
251	Role of ?1- and ?2-adrenoceptor polymorphisms in heart failure: a case-control study. <i>European Heart Journal</i> , 2004, 25, 1534-1541.	1.0	46
252	Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes. <i>Cardiology</i> , 2010, 115, 29-36.	0.6	45

#	ARTICLE	IF	CITATIONS
253	Liver function tests in patients with acute heart failure and associated outcomes: insights from <sc>ASCENDâ€HF</sc>. European Journal of Heart Failure, 2016, 18, 424-432.	2.9	45
254	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77.	1.9	45
255	Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. International Journal of Cardiology, 2017, 234, 53-57.	0.8	45
256	Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Naâ€K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?. Heart Failure Reviews, 2009, 14, 277-287.	1.7	44
257	Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403.	1.9	44
258	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 112-120.	2.9	44
259	Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). Journal of Cardiac Failure, 2008, 14, 777-784.	0.7	43
260	Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure. JACC: Heart Failure, 2015, 3, 751-761.	1.9	43
261	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	1.2	43
262	Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. European Heart Journal, 2018, 39, 1295-1303.	1.0	43
263	Acute heart failure: More questions than answers. Progress in Cardiovascular Diseases, 2020, 63, 599-606.	1.6	43
264	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <sc>ACTIVE</sc> study, an <sc>Italian nationwide survey</sc>. European Journal of Heart Failure, 2022, 24, 1377-1386.	2.9	43
265	Risk following hospitalization in stable chronic systolic heart failure. European Journal of Heart Failure, 2013, 15, 885-891.	2.9	42
266	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 304-314.	2.9	42
267	Clinical profiles in acute heart failure: an urgent need for a new approach. ESC Heart Failure, 2019, 6, 464-474.	1.4	42
268	Rationale and design of the AFFIRMâ€AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	2.9	42
269	Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance. PLoS ONE, 2012, 7, e48283.	1.1	41
270	Coronavirus 2019 Disease (COVIDâ€19), Systemic Inflammation, and Cardiovascular Disease. Journal of the American Heart Association, 2020, 9, e017756.	1.6	41



#	ARTICLE	IF	CITATIONS
271	Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1759-1767.	2.9	41
272	Acute Decompensated Heart Failure Update. <i>Current Cardiology Reviews</i> , 2014, 11, 53-62.	0.6	41
273	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	2.9	41
274	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
275	Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. <i>Clinical Research in Cardiology</i> , 2012, 101, 663-672.	1.5	40
276	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	0.6	40
277	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	0.7	39
278	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	0.7	38
279	Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 874-881.	0.6	38
280	Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8, CMC.S14016.	0.6	37
281	Time is prognosis™ in heart failure: time to treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	1.4	37
282	Prognostic Value of Cardiopulmonary Exercise Variables in Chronic Heart Failure Patients With or Without Beta-Blocker Therapy. <i>American Journal of Cardiology</i> , 2006, 98, 500-503.	0.7	36
283	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1128-1135.	2.9	36
284	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	1.2	36
285	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
286	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. <i>International Journal of Cardiology</i> , 2016, 203, 1067-1072.	0.8	36
287	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-ORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
288	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35

#	ARTICLE	IF	CITATIONS
289	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	35
290	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	0.8	35
291	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
292	Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. <i>EuroIntervention</i> , 2020, 16, 413-420.	1.4	35
293	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	0.8	34
294	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	2.9	34
295	Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 97-104.	0.8	34
296	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	2.9	34
297	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. <i>Europace</i> , 2021, 23, 1603-1611.	0.7	34
298	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2022, 24, 365-374.	2.9	34
299	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2408-2421.	1.2	34
300	Quantitative Analysis of Right Ventricular (RV) Function With Echocardiography in Chronic Heart Failure With No or Mild RV Dysfunction. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 247-255.	0.8	33
301	Heart failure and anemia: Effects on prognostic variables. <i>European Journal of Internal Medicine</i> , 2017, 37, 56-63.	1.0	33
302	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	2.9	33
303	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
304	Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?. <i>European Journal of Heart Failure</i> , 2022, 24, 442-454.	2.9	33
305	Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1843-1851.	2.3	33
306	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. <i>European Journal of Heart Failure</i> , 2011, 13, 1253-1260.	2.9	32

#	ARTICLE	IF	CITATIONS
307	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1046-1055.	0.8	32
308	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	2.9	32
309	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	1.5	32
310	Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. <i>European Journal of Pharmacology</i> , 2018, 828, 80-88.	1.7	32
311	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. <i>Clinical Research in Cardiology</i> , 2021, 110, 1020-1028.	1.5	32
312	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
313	Impact of mitral regurgitation in patients with worsening heart failure: insights from <sc>BIOSTAT</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
314	<sc>COVID</sc>-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
315	Patiomer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the <sc>DIAMOND</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	2.9	32
316	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
317	Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2011, 4, 361-368.	1.6	31
318	Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. <i>ESC Heart Failure</i> , 2020, 7, 381-399.	1.4	31
319	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	2.9	30
320	Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?. <i>European Journal of Heart Failure</i> , 2015, 17, 936-944.	2.9	30
321	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	0.7	30
322	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
323	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> . 2022, 24, 132-142.	2.9	30
324	Exchange of $\beta$ -blockers in heart failure patients. Experiences from the poststudy phase of COMET (the) Tj ETQq0 0.0rgBT /Overlock 10	2.9	29

#	ARTICLE	IF	CITATIONS
325	Role of $\beta_1$ - and $\beta_2$ -adrenergic receptor polymorphisms and their combination in heart failure: A case-control study. <i>European Journal of Heart Failure</i> , 2006, 8, 131-135.	2.9	29
326	n-3 PUFAs and cardiovascular disease prevention. <i>Future Cardiology</i> , 2010, 6, 343-350.	0.5	29
327	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Circulation Journal</i> , 2015, 79, 583-591.	0.7	29
328	Obstructive sleep apnoea—hypopnoea and arrhythmias. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 490-500.	0.6	29
329	Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 3547-3556.	1.4	29
330	Cardiac remodelling—Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
331	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013, 18, 797-813.	1.7	28
332	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <i>VERITAS</i> study. <i>European Journal of Heart Failure</i> , 2014, 16, 1362-1371.	2.9	28
333	Management of acute heart failure in elderly patients. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 422-430.	0.7	28
334	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 534-548.	0.4	28
335	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies ( <i>VERITAS</i> ). <i>European Journal of Heart Failure</i> , 2017, 19, 739-747.	2.9	28
336	Prognostic role of $\beta$ -blocker selectivity and dosage regimens in heart failure patients. Insights from the <i>MECKI</i> score database. <i>European Journal of Heart Failure</i> , 2017, 19, 904-914.	2.9	28
337	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	1.5	28
338	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
339	Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. <i>JACC: Heart Failure</i> , 2020, 8, 973-983.	1.9	28
340	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	2.9	28
341	A year in heart failure: an update of recent findings. <i>ESC Heart Failure</i> , 2021, 8, 4370-4393.	1.4	28
342	Amino acids and derivatives, a new treatment of chronic heart failure?. <i>Heart Failure Reviews</i> , 2015, 20, 39-51.	1.7	27

#	ARTICLE	IF	CITATIONS
343	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016, 22, 815-822.	0.7	27
344	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	1.5	27
345	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
346	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
347	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
348	Rationale and Design of the Enoximone Clinical Trials Program. <i>Journal of Cardiac Failure</i> , 2005, 11, 659-669.	0.7	26
349	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>TJ ETQq1 1 0.784314 rgBT /Over</i>	0.7	26
350	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019, 7, 970-979.	1.9	26
351	In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. <i>ESC Heart Failure</i> , 2020, 7, 2650-2661.	1.4	26
352	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	2.9	26
353	Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice. <i>Circulation: Heart Failure</i> , 2021, 14, e008527.	1.6	26
354	Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. <i>ESC Heart Failure</i> , 2022, 9, 1507-1523.	1.4	26
355	Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: Results of the oral enoximone in intravenous inotrope-dependent subjects trial. <i>American Heart Journal</i> , 2007, 154, 861-869.	1.2	25
356	Elastic properties of the ascending aorta in patients with $\alpha$ 1-antitrypsin deficiency (Z homozygotes). <i>Heart</i> , 2012, 98, 1354-1358.	1.2	25
357	Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. <i>Heart Failure Reviews</i> , 2012, 17, 271-282.	1.7	25
358	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. <i>International Journal of Cardiology</i> , 2013, 168, 5078-5081.	0.8	25
359	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-HF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	2.9	25
360	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 218-226.	2.9	25

#	ARTICLE	IF	CITATIONS
361	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	1.9	25
362	The prognostic value of serial troponin measurements in patients admitted for COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 3504-3511.	1.4	25
363	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	2.9	24
364	Agents with vasodilator properties in acute heart failure: how to design successful trials. <i>European Journal of Heart Failure</i> , 2015, 17, 652-664.	2.9	24
365	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 1586-1595.	2.9	24
366	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
367	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	2.9	24
368	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. <i>Nutrients</i> , 2021, 13, 257.	1.7	24
369	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
370	SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study. <i>Clinical Research in Cardiology</i> , 2021, 110, 1822-1831.	1.5	24
371	Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. <i>American Journal of the Medical Sciences</i> , 2014, 347, 271-276.	0.4	23
372	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1056-1065.	0.3	23
373	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	0.5	23
374	Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 350-352.	2.9	23
375	N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 828-839.	0.6	23
376	Ascending Aortic Dimensions in Hypertensive Subjects: Reference Values for Two-Dimensional Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 827-837.	1.2	23
377	Redefining biomarkers in heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 237-253.	1.7	23
378	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	1.6	23

#	ARTICLE	IF	CITATIONS
379	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 368-377.	1.4	23
380	Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?. <i>European Heart Journal</i> , 2020, 41, 3094-3094.	1.0	23
381	Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. <i>Journal of Infection</i> , 2021, 82, e4-e7.	1.7	23
382	Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 149-156.	0.6	23
383	Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment. <i>European Journal of Heart Failure</i> , 2022, 24, 959-975.	2.9	23
384	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. <i>Journal of Cardiac Failure</i> , 2010, 16, 714-719.	0.7	22
385	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
386	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-HF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	1.4	22
387	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 539-546.	1.4	22
388	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1999-2007.	2.9	22
389	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
390	Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1493-1503.	2.9	22
391	Role of Aliskiren on Arterial Stiffness and Endothelial Function in Patients With Primary Hypertension. <i>Journal of Clinical Hypertension</i> , 2014, 16, 202-206.	1.0	21
392	Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 3, 6-14.	0.5	21
393	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure—Application of Metabolic Exercise Cardiac Kidney Indexes Score. <i>Circulation Journal</i> , 2015, 79, 2608-2615.	0.7	21
394	Role of different vascular approaches on transcatheter aortic valve implantation outcome. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 279-285.	0.6	21
395	Coronavirus disease 2019 and cardiovascular implications. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 725-732.	0.6	21
396	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-HF2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	2.9	21

#	ARTICLE	IF	CITATIONS
397	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization – the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e173-e177.	0.8	21
398	Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1992, 70, 629-634.	0.7	20
399	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , 2003, 91, 10-17.	0.7	20
400	Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly? <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 23, 657-664.	0.6	20
401	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. <i>European Journal of Heart Failure</i> , 2003, 5, 803-809.	2.9	20
402	CA 125 Tumoral Marker Plasma Levels Relate to Systolic and Diastolic Ventricular Function and to the Clinical Status of Patients with Chronic Heart Failure. <i>Echocardiography</i> , 2008, 25, 955-960.	0.3	20
403	Old and New Intravenous Inotropic Agents in the Treatment of Advanced Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 97-106.	1.6	20
404	Functional and Hemodynamic Cardiac Determinants of Exercise Capacity in Patients With Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 1336-1341.	0.7	20
405	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013, 168, 3691-3697.	0.8	20
406	Systolic blood pressure reduction during the first 24h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018, 20, 317-322.	2.9	20
407	The New Heart Failure Association Definition of Advanced Heart Failure. <i>Cardiac Failure Review</i> , 2019, 5, 5-8.	1.2	20
408	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 436-444.	2.9	20
409	Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation. <i>Current Heart Failure Reports</i> , 2021, 18, 99-106.	1.3	20
410	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
411	Higher doses of loop diuretics limit up-titration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20
412	Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome. <i>Canadian Journal of Cardiology</i> , 2022, 38, 320-329.	0.8	20
413	Noninvasive Assessment of Endothelial Function: The Classic Methods and the New Peripheral Arterial Tonometry. <i>Journal of Investigative Medicine</i> , 2014, 62, 856-864.	0.7	19
414	The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 597-602.	0.6	19



#	ARTICLE	IF	CITATIONS
415	Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure. <i>Journal of Interventional Cardiology</i> , 2015, 28, 61-68.	0.5	19
416	Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis. <i>American Heart Journal</i> , 2015, 170, 531-542.e1.	1.2	19
417	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
418	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. <i>Canadian Journal of Cardiology</i> , 2016, 32, 754-759.	0.8	19
419	Sinus Node Dysfunction in a Young Patient With COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1240-1244.	0.3	19
420	Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€“CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
421	Thromboembolism in Heart Failure Patients in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2021, 9, 243-253.	1.9	18
422	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. <i>European Journal of Heart Failure</i> , 2022, 24, 916-926.	2.9	18
423	Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Cardiology</i> , 2010, 117, 190-196.	0.6	17
424	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
425	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2017, 120, 1090-1097.	0.7	17
426	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	1.5	17
427	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1470.	1.8	17
428	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	2.9	17
429	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
430	Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: old but gold. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1177-1187.	0.8	17
431	Treatment of heart failure in the elderly: never say it's too late. <i>European Heart Journal</i> , 2008, 30, 391-393.	1.0	16
432	Endpoints in stem cell trials in ischemic heart failure. <i>Stem Cell Research and Therapy</i> , 2015, 6, 159.	2.4	16

#	ARTICLE	IF	CITATIONS
433	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. <i>European Journal of Internal Medicine</i> , 2015, 26, 515-520.	1.0	16
434	Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. <i>Clinical Research in Cardiology</i> , 2015, 104, 1078-1087.	1.5	16
435	N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment. <i>Journal of Cardiac Failure</i> , 2015, 21, 930-934.	0.7	16
436	In-hospital worsening heart failure in patients admitted for acute heart failure. <i>International Journal of Cardiology</i> , 2016, 225, 353-361.	0.8	16
437	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	1.5	16
438	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
439	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	0.7	16
440	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 394-404.	1.4	16
441	Evidence-Based Management of Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2021, 37, 621-631.	0.8	16
442	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	0.7	16
443	??-Blockade in Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 3-14.	1.0	15
444	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. <i>European Journal of Heart Failure</i> , 2010, 12, 1238-1246.	2.9	15
445	Use of Inotropic Agents in Patients with Advanced Heart Failure. <i>Drugs</i> , 2011, 71, 515-525.	4.9	15
446	Can we prevent or treat renal dysfunction in acute heart failure?. <i>Heart Failure Reviews</i> , 2012, 17, 291-303.	1.7	15
447	Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results. <i>Europace</i> , 2013, 15, 1475-1481.	0.7	15
448	Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion?. <i>European Journal of Heart Failure</i> , 2016, 18, 1278-1286.	2.9	15
449	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
450	Heart failure 2016: still more questions than answers. <i>International Journal of Cardiology</i> , 2017, 227, 766-777.	0.8	15

#	ARTICLE	IF	CITATIONS
451	Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study. <i>Monaldi Archives for Chest Disease</i> , 2018, 88, 934.	0.3	15
452	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
453	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	2.9	15
454	Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 899-906.	0.6	15
455	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
456	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 32</i>	2.9	15
457	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	2.9	15
458	Left ventricular ejection fraction as the primary heart failure phenotyping parameter. <i>European Journal of Heart Failure</i> , 2022, 24, 1158-1161.	2.9	15
459	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	1.0	15
460	Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. <i>Clinical Research in Cardiology</i> , 2010, 99, 75-82.	1.5	14
461	Can we improve the treatment of congestion in heart failure?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1369-1379.	0.9	14
462	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	2.9	14
463	High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure. <i>Circulation</i> , 2017, 135, 1506-1508.	1.6	14
464	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	14
465	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3425-3434.	2.0	14
466	Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1944-1953.	1.4	14
467	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i>	0.7	14
468	Mode of Death After Acute Heart Failure Hospitalization – A Clue to Possible Mechanisms –. <i>Circulation Journal</i> , 2016, 80, 17-23.	0.7	13

#	ARTICLE	IF	CITATIONS
469	Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 859-865.	0.6	13
470	Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12323.	1.1	13
471	Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. <i>ESC Heart Failure</i> , 2018, 5, 267-274.	1.4	13
472	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
473	Dose-dependent efficacy of $\beta$ -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	0.8	13
474	Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: A case-control study. <i>Echocardiography</i> , 2019, 36, 1118-1122.	0.3	13
475	Congestion in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 575-586.	1.0	13
476	Creatine deficiency and heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 1605-1616.	1.7	13
477	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, S36-S45.	0.8	13
478	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011, 100, 745-753.	1.5	12
479	Six-year prognosis of diabetic patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 376-383.	1.7	12
480	ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care. <i>European Heart Journal Supplements</i> , 2017, 19, D89-D101.	0.0	12
481	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	1.9	12
482	Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3536-3544.	1.4	12
483	Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The "macro-hub" experience. <i>IJC Heart and Vasculature</i> , 2020, 31, 100662.	0.6	12
484	Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak. <i>International Journal of Cardiology</i> , 2020, 312, 24-26.	0.8	12
485	Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. <i>European Journal of Heart Failure</i> , 2022, 24, 1460-1466.	2.9	12
486	A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 139-152.	1.3	11

#	ARTICLE	IF	CITATIONS
487	Years needed to treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , 2009, 11, 256-263.	2.9	11
488	Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III. <i>Cardiology</i> , 2010, 116, 292-301.	0.6	11
489	Tachycardia After a Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2013, 1, 497-499.	1.9	11
490	Echocardiographic evaluation in subjects with $\alpha_1$ -antitrypsin deficiency. <i>European Journal of Clinical Investigation</i> , 2015, 45, 949-954.	1.7	11
491	Ivabradine during cardiogenic shock: A clinical case and review of the literature. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015, 44, 57-58.	0.8	11
492	Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 736-745.	1.9	11
493	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	0.8	11
494	Cardiorenal Interactions. <i>Heart Failure Clinics</i> , 2016, 12, 335-347.	1.0	11
495	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	11
496	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 783-792.	0.7	11
497	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. <i>Drugs</i> , 2019, 79, 1543-1556.	4.9	11
498	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
499	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
500	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25.	1.4	11
501	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	0.8	11
502	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021, 23, 1170-1181.	2.9	11
503	Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1626-1635.	0.7	11
504	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1680-1688.	0.8	11

#	ARTICLE	IF	CITATIONS
505	Pharmacokinetic and Pharmacodynamic Characteristics of $\beta$ -Blockers: When Differences May Matter. <i>Journal of Cardiac Failure</i> , 2006, 12, 177-181.	0.7	10
506	Right Ventricular Thrombus and Pulmonary Thromboembolism/Thrombosis in Behçet's Disease: A Case Report. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1079.e5-1079.e7.	1.2	10
507	Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor Therapy. <i>Clinical Cardiology</i> , 2014, 37, 738-743.	0.7	10
508	Is There a Role for Ivabradine Beyond its Conventional Use?. <i>Cardiovascular Therapeutics</i> , 2014, 32, 189-192.	1.1	10
509	Prognostic value of $\langle \text{RV} \rangle$ isovolumic acceleration and tissue strain in moderate $\langle \text{HF} \rangle$ $\langle \text{EF} \rangle$ . <i>European Journal of Clinical Investigation</i> , 2015, 45, 1052-1059.	1.7	10
510	Effects of serelexin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	1.2	10
511	Updates in heart failure: what last year brought to us. <i>ESC Heart Failure</i> , 2018, 5, 989-1007.	1.4	10
512	Elastic properties of ascending aorta and ventricular-arterial coupling in women with previous pregnancy complicated by HELLP syndrome. <i>Journal of Hypertension</i> , 2019, 37, 356-364.	0.3	10
513	Inappropriate left ventricular mass after preeclampsia: another piece of the puzzle Inappropriate LVM and PE. <i>Hypertension Research</i> , 2019, 42, 522-529.	1.5	10
514	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
515	ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3200-3200.	1.0	10
516	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF <sup>2</sup> study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	2.9	10
517	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIostat-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
518	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
519	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
520	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 2212-2220.	1.0	10
521	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10
522	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	2.9	10

#	ARTICLE	IF	CITATIONS
523	Nuclear cardiology and heart failure. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 2068-2080.	3.3	9
524	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 173-188.	0.6	9
525	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	1.2	9
526	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
527	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	2.9	9
528	New drugs for the treatment of chronic heart failure with a reduced ejection fraction. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 650-659.	0.6	9
529	The brain-heart connection: a multiple sclerosis relapse presenting as Takotsubo Syndrome. A case report and literature review. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	9
530	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	2.9	9
531	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e019123.	1.6	9
532	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. <i>ESC Heart Failure</i> , 2021, 8, 4717-4736.	1.4	9
533	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	2.9	9
534	Left Atrial Volume Index and Outcome after Transcatheter Edge-to-Edge Valve Repair for Secondary Mitral Regurgitation. <i>European Journal of Heart Failure</i> , 0, , .	2.9	9
535	Dopaminergic Drugs in Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 732-740.	0.8	8
536	Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. <i>Therapeutic Advances in Respiratory Disease</i> , 2009, 3, 11-14.	1.0	8
537	Can we prevent or treat renal dysfunction in chronic heart failure?. <i>Heart Failure Reviews</i> , 2012, 17, 283-290.	1.7	8
538	Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition?. <i>Clinical Research in Cardiology</i> , 2015, 104, 614-616.	1.5	8
539	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	1.5	8
540	Integrating electronic health records into the study of heart failure: promises and pitfalls. <i>European Journal of Heart Failure</i> , 2017, 19, 1128-1130.	2.9	8

#	ARTICLE	IF	CITATIONS
541	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	1.3	8
542	A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421.	0.6	8
543	Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a caseâ€“control study. <i>Internal and Emergency Medicine</i> , 2019, 14, 1279-1285.	1.0	8
544	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	1.8	8
545	Publication Rates of Heart Failure Clinical Trials Remain Low. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3151-3161.	1.2	8
546	Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. <i>American Journal of Cardiology</i> , 2021, 143, 51-59.	0.7	8
547	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2022, 27, 1147-1163.	1.7	8
548	Amended <sc>STRONGâ€“HF</sc> study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	2.9	8
549	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022288.	1.6	8
550	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	0.7	8
551	Responder analysis for improvement in sixâ€“minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, , .	2.9	8
552	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8
553	Prognostic significance of serum potassium in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2357-2366.	1.4	8
554	Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1994, 1, 27-33.	0.7	7
555	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. <i>International Journal of Cardiology</i> , 2011, 150, 368-369.	0.8	7
556	Elastic Aortic Properties in Patients with X Syndrome. <i>Heart Lung and Circulation</i> , 2014, 23, 114-118.	0.2	7
557	Negotiating renal dysfunction when treating patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 113-122.	0.6	7
558	Implications of serial measurements of natriuretic peptides in heart failure: insights from <sc>BIOSTATâ€“CHF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	2.9	7



#	ARTICLE	IF	CITATIONS
559	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
560	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	0.7	7
561	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
562	Percutaneous Edge-to-Edge Mitral Valve Repair: Beyond the Left Heart. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 1038-1045.	1.2	7
563	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	1.9	7
564	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. <i>Drugs</i> , 2022, 82, 375-405.	4.9	7
565	Prevalence and Rate of Resolution of Left Atrial Thrombus in Patients with Non-Valvular Atrial Fibrillation: A Two-Center Retrospective Real-World Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1520.	1.0	7
566	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, . .	2.9	7
567	Dopamine receptors in the stellate ganglion of the dog. <i>European Journal of Pharmacology</i> , 1989, 164, 265-272.	1.7	6
568	Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 182-187.	0.6	6
569	Measurement of the Myocardial Performance Index in Ambulatory Patients with Heart Failure: Correlation with Other Clinical and Echocardiographic Parameters and Independent Prognostic Value. <i>Echocardiography</i> , 2010, 27, 123-129.	0.3	6
570	The puzzle of kidney dysfunction in heart failure: an introduction. <i>Heart Failure Reviews</i> , 2012, 17, 129-131.	1.7	6
571	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure – Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	0.8	6
572	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
573	Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results. <i>European Journal of Heart Failure</i> , 2020, 22, 1849-1851.	2.9	6
574	Thrombotic risk in patients with COVID-19. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 277.	0.5	6
575	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 108, 270-273.	1.5	6
576	Cardiogenic Shock due to COVID-19-Related Myocarditis in a 19-Year-Old Autistic Patient. <i>Journal of Medical Cases</i> , 2020, 11, 207-210.	0.4	6

#	ARTICLE	IF	CITATIONS
577	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 569-78.	0.9	6
578	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1009-1019.	2.9	6
579	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 439-446.	0.6	6
580	Long-Term Changes in Left Ventricular Mass, Chamber Size and Function after Valve Replacement in Patients with Severe Aortic Stenosis and Depressed Ejection Fraction. <i>Cardiology</i> , 1997, 88, 315-322.	0.6	5
581	Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?. <i>Circulation: Heart Failure</i> , 2013, 6, 869-876.	1.6	5
582	Effects of transcatheter aortic valve implantation on ascending aorta wall elastic properties: Tissue Doppler imaging and strain Doppler echocardiography study. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 4, 198-202.	0.5	5
583	Characteristics and mid-term follow-up of a single-center population affected by Tako-Tsubo cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 326-330.	0.6	5
584	Prognostic evaluation of the elastic properties of the ascending aorta in dilated cardiomyopathy. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12950.	1.7	5
585	June 2020 at a glance: focus on COVID-19, quality of life and comorbidities. <i>European Journal of Heart Failure</i> , 2020, 22, 917-918.	2.9	5
586	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
587	Maternal hemodynamics, arterial stiffness and elastic aortic properties in twin pregnancy. <i>Physiological Measurement</i> , 2020, 41, 125001.	1.2	5
588	Coronary Artery Disease and High Altitude: Unresolved Issues. <i>Research in Cardiovascular Medicine</i> , 2016, 5, e32645.	0.2	5
589	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
590	Patient with heart failure: importance to treat valvular diseases. <i>European Heart Journal Supplements</i> , 2020, 22, P38-P41.	0.0	5
591	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	1.2	5
592	Serelaxin a novel treatment for acute heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 549-557.	1.3	4
593	September 2016 at a glance: pregnancy, hypertrophic cardiomyopathy, epidemiology, medical treatment. <i>European Journal of Heart Failure</i> , 2016, 18, 1091-1092.	2.9	4
594	Carnosine: Potential aid for diabetes and cardiovascular disease. <i>Obesity</i> , 2016, 24, 989-989.	1.5	4

#	ARTICLE	IF	CITATIONS
595	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 637-643.	0.5	4
596	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
597	Iron deficiency in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 706-716.	0.6	4
598	January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care. <i>European Journal of Heart Failure</i> , 2019, 21, 1-2.	2.9	4
599	January 2020 at a glance: translational medicine, predictors of outcome and treatments. <i>European Journal of Heart Failure</i> , 2020, 22, 1-2.	2.9	4
600	March 2021 at a glance: focus on epidemiology, prevention and COVID-19. <i>European Journal of Heart Failure</i> , 2021, 23, 347-349.	2.9	4
601	Why we love heart failure: an introduction to the universal definition of heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 350-351.	2.9	4
602	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 828-831.	0.6	4
603	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, S36-S45.	0.8	4
604	Unusual intracardiac thrombosis in two patients with coronavirus disease 2019 (COVID-19): case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa518.	0.3	4
605	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
606	Biomarker changes as surrogate endpoints in early phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
607	Diagnostic accuracy of rest-exercise first pass ventriculography with a fast single crystal gamma camera in detecting coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1987, 13, 213-220.	2.2	3
608	Beta Blockers in Heart Failure: Issues in Management of Individual Patients. <i>Heart Failure Reviews</i> , 1999, 4, 65-78.	1.7	3
609	Current guidelines in the pharmacological management of chronic heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S11.	1.0	3
610	β-blocker therapy of heart failure: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 289-298.	0.9	3
611	Antagonism of the Sympathetic Nervous System in Heart Failure. , 2011, , 674-693.		3
612	Response to Letter Regarding Article, "Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? The Role of Congestion and Its Interaction With Renal Function" Circulation: Heart Failure, 2012, 5, .	1.6	3

#	ARTICLE	IF	CITATIONS
613	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	1.2	3
614	Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1114-1116.	1.2	3
615	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , 2015, 20, 393-400.	1.7	3
616	Revisiting Cardiac Injury During Acute Heart Failure: Further Characterization and a Possible Target for Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 141-146.	0.7	3
617	July 2016 at a glance: the critical role of comorbidities. <i>European Journal of Heart Failure</i> , 2016, 18, 735-735.	2.9	3
618	August 2016 at a glance: the new ESC guidelines, and pathophysiology, epidemiology and prognosis of heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 889-890.	2.9	3
619	Can Carbohydrate Antigen-125 Be a New Biomarker to Guide Heart Failure Treatment?. <i>JACC: Heart Failure</i> , 2016, 4, 844-846.	1.9	3
620	Cardiac ANCA-associated vasculitis mimicking an acute coronary syndrome. <i>International Journal of Cardiology</i> , 2016, 214, 200-201.	0.8	3
621	January 2017 at a glance: oncology, diabetes and antidiabetic treatment, pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017, 19, 7-8.	2.9	3
622	Arrhythmias and cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e145-e148.	0.6	3
623	October 2017 at a glance: phenotyping heart failure, comorbidities, use of evidence-based therapy and new treatments. <i>European Journal of Heart Failure</i> , 2017, 19, 1216-1217.	2.9	3
624	June 2018 at a glance: peripartum cardiomyopathy and pathophysiology, prognosis, and device therapy of heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 949-950.	2.9	3
625	May 2020 at a glance: ischaemic heart failure and sex-related differences. <i>European Journal of Heart Failure</i> , 2020, 22, 761-762.	2.9	3
626	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.4	3
627	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3
628	The impact of COVID-19 pandemic on AMI and stroke mortality in Lombardy: Evidence from the epicenter of the pandemic. <i>PLoS ONE</i> , 2021, 16, e0257910.	1.1	3
629	Diuretic Resistance and Chronic Heart Failure. , 2020, , 121-135.		3
630	Right ventricular deformation and right ventricular-arterial coupling in patients with heart failure due to severe aortic stenosis undergoing TAVI: long-term results. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 150-163.	0.5	3

#	ARTICLE	IF	CITATIONS
631	Ejection fraction in heart failure: just become Emperor's new clothes?. <i>European Journal of Heart Failure</i> , 2022, 24, 351-352.	2.9	3
632	Sex-related differences in patients with coronavirus disease 2019. <i>Journal of Cardiovascular Medicine</i> , 2022, Publish Ahead of Print, 254-263.	0.6	3
633	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009199.	1.6	3
634	Endothelial dysfunction in COVID-19 patients assessed with Endo-PAT2000. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.3	3
635	Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion. <i>American Journal of Cardiology</i> , 2022, 171, 105-114.	0.7	3
636	Clinical efficacy of ibopamine in patients with chronic heart failure. <i>Clinical Cardiology</i> , 1995, 18, 1-22-1-31.	0.7	2
637	Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. <i>General Pharmacology</i> , 1996, 27, 1255-1259.	0.7	2
638	ESSENTIAL â€” The Studies of Oral Enoximone Therapy in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2005, 11, 721.	0.7	2
639	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinezâ€™elles. <i>European Journal of Heart Failure</i> , 2007, 9, 1224-1225.	2.9	2
640	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. <i>Journal of Cardiac Failure</i> , 2009, 15, S74.	0.7	2
641	The EJHF last Editor's legacy: how can a high impact factor be built?. <i>ESC Heart Failure</i> , 2015, 2, 50-57.	1.4	2
642	February 2017 at a glance: fibrosis, acute heart failure and neurologic abnormalities. <i>European Journal of Heart Failure</i> , 2017, 19, 165-166.	2.9	2
643	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	0.8	2
644	What will be the impact of sacubitril/valsartan in clinical practice?. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e88-e90.	0.6	2
645	September 2018 at a glance: coâ€™morbidity, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1245-1246.	2.9	2
646	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , 2022, 27, 135-145.	1.7	2
647	Renal failure after trans-catheter aortic valve implantation. <i>European Journal of Internal Medicine</i> , 2021, 83, 86-87.	1.0	2
648	Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fueled controversy. <i>European Journal of Heart Failure</i> , 2021, 23, 486-488.	2.9	2

#	ARTICLE	IF	CITATIONS
649	Chapter 49 Acute heart failure: epidemiology, classification, and pathophysiology. , 2011, , .		2
650	Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review. Recent Patents on Cardiovascular Drug Discovery, 2014, 8, 204-215.	1.5	2
651	December 2020 at a glance: focus on <scp>COVID</scp>â€19, comorbidities and palliative care. European Journal of Heart Failure, 2020, 22, 2173-2174.	2.9	2
652	Risk assessment for a high-altitude alpinist with coronary artery disease. Heart, Lung and Vessels, 2015, 7, 268-70.	0.4	2
653	Sarcopenia detected by computed tomography: a simple tool for screening transcatheter aortic valve implantation candidates. Journal of Cardiovascular Medicine, 2022, 23, 69-70.	0.6	2
654	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. Clinical and Experimental Rheumatology, 2016, 34, 352.	0.4	2
655	Impact of Continuous Flow Left Ventricular Assist Device on Heart Transplant Candidates: A Multi-State Survival Analysis. Journal of Clinical Medicine, 2022, 11, 3425.	1.0	2
656	What we have learnt in valvular heart disease from our journal. Journal of Cardiovascular Medicine, 2022, 23, 427-429.	0.6	2
657	A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. Cardiovascular Drugs and Therapy, 1988, 1, 513-521.	1.3	1
658	Selective or nonselective Î²2-adrenergic blockade in patients with congestive heart failure. Current Cardiology Reports, 2000, 2, 252-257.	1.3	1
659	Anemia and Heart Failure: A Cause of Progression or Only a Consequence?. Heart International, 2007, 3, 182618680700300.	0.4	1
660	Anaemia and heart failure. Open Medicine (Poland), 2011, 6, 11-25.	0.6	1
661	Not time to RELAX in acute heart failure â€ Authors' reply. Lancet, The, 2013, 381, 1813-1814.	6.3	1
662	Echocardiographic elastic properties of ascending aorta and their relationship with exercise capacity in patients with non-ischemic dilated cardiomyopathy. International Journal of Cardiology Heart & Vessels, 2014, 3, 78-81.	0.5	1
663	Echocardiographic Evaluation of Aortic Atheromas in Patients With Aortic Stenosis. Journal of Ultrasound in Medicine, 2015, 34, 105-110.	0.8	1
664	April 2015 at a glance. European Journal of Heart Failure, 2015, 17, 347-347.	2.9	1
665	The European Journal of Heart Failure now and in the years to come: a salutation from the incoming Editorâ€inâ€Chief.. European Journal of Heart Failure, 2015, 17, 119-121.	2.9	1
666	June 2016 at a glance: epidemiology, renal impairment, heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 587-587.	2.9	1

#	ARTICLE	IF	CITATIONS
667	April 2016 at a glance. Focus on cardiac remodeling, biomarkers and treatment. European Journal of Heart Failure, 2016, 18, 345-346.	2.9	1
668	Understanding worsening heart failure as a therapeutic target: another step forward?. European Journal of Heart Failure, 2017, 19, 996-1000.	2.9	1
669	September 2017 at a glance: epidemiology, prognosis, Mediterranean diet and different viewpoints on aspirin. European Journal of Heart Failure, 2017, 19, 1084-1085.	2.9	1
670	August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization. European Journal of Heart Failure, 2017, 19, 969-970.	2.9	1
671	November 2017 at a glance: quality of care and disease management. European Journal of Heart Failure, 2017, 19, 1351-1352.	2.9	1
672	December 2017 at a glance: left ventricular ejection fraction, exercise capacity, peripartum cardiomyopathy. European Journal of Heart Failure, 2017, 19, 1562-1563.	2.9	1
673	November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure. European Journal of Heart Failure, 2018, 20, 1503-1504.	2.9	1
674	August 2018 at a glance: patients' outcomes, obesity and medical therapy. European Journal of Heart Failure, 2018, 20, 1167-1168.	2.9	1
675	Assessment of Congestion in Acute Heart Failure: When Simplicity Does Not Go Along With Accuracy. Journal of Cardiac Failure, 2018, 24, 550-552.	0.7	1
676	July 2019 at a glance: imaging of congestion, sodium-glucose co-transporter 2 inhibitors, myocardial function and MitraClip trials. European Journal of Heart Failure, 2019, 21, 821-822.	2.9	1
677	February 2019 at a glance: pathophysiology, exercise capacity, diuretics and valve disease. European Journal of Heart Failure, 2019, 21, 135-136.	2.9	1
678	December 2019 at a glance: economic burden, comorbidities, and prognosis. European Journal of Heart Failure, 2019, 21, 1485-1486.	2.9	1
679	Acute Heart Failure. , 2020, , 501-519.		1
680	If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation. European Journal of Heart Failure, 2020, 22, 1888-1890.	2.9	1
681	November 2020 at a glance: focus on comorbidities and medical treatment. European Journal of Heart Failure, 2020, 22, 1937-1938.	2.9	1
682	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. Journal of Cardiovascular Medicine, 2020, 21, 634-640.	0.6	1
683	Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease—Reply. JAMA Cardiology, 2020, 5, 1306.	3.0	1
684	March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis. European Journal of Heart Failure, 2020, 22, 389-390.	2.9	1

#	ARTICLE	IF	CITATIONS
685	FC 021 EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
686	Best of European Journal of Heart Failure at the <scp>ESC</scp>/<scp>HFA</scp> Heart Failure Congress 2021. <i>European Journal of Heart Failure</i> , 2021, 23, 1424-1427.	2.9	1
687	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , 2021, 240, 73-80.	1.2	1
688	Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1979-1980.	2.9	1
689	March 2022 at a glance: focus on medical therapy, prevention and comorbidities. <i>European Journal of Heart Failure</i> , 2022, 24, 403-405.	2.9	1
690	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 792804.	1.1	1
691	Cardiac biomarkers and mortality in COVID-19 infection: A review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	1
692	Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 513-517.	1.3	0
693	Endothelial Damage Due to Air Pollution. <i>Heart International</i> , 2006, 2, 182618680600200.	0.4	0
694	Managing heart failure in the very old. <i>Aging Health</i> , 2006, 2, 253-275.	0.3	0
695	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. , 0, , 1-30.		0
696	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy". <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 335-336.	1.3	0
697	The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 331-343.	1.0	0
698	Reply. <i>Journal of Clinical Hypertension</i> , 2014, 16, 694-694.	1.0	0
699	A Case of a Fistula between Myxoma and a Branch of Right Coronary Artery. <i>Echocardiography</i> , 2014, 31, E289-E290.	0.3	0
700	June 2015 at a glance. <i>European Journal of Heart Failure</i> , 2015, 17, 535-535.	2.9	0
701	July 2015 at a glance. <i>European Journal of Heart Failure</i> , 2015, 17, 641-641.	2.9	0
702	September 2015 at a glance. <i>European Journal of Heart Failure</i> , 2015, 17, 847-847.	2.9	0



#	ARTICLE	IF	CITATIONS
703	November 2015 at a glance. European Journal of Heart Failure, 2015, 17, 1085-1085.	2.9	0
704	December 2015 at a glance. European Journal of Heart Failure, 2015, 17, 1209-1209.	2.9	0
705	October 2015 at a glance. European Journal of Heart Failure, 2015, 17, 987-987.	2.9	0
706	August 2015 at a glance. European Journal of Heart Failure, 2015, 17, 749-749.	2.9	0
707	March 2015 at a glance. European Journal of Heart Failure, 2015, 17, 235-236.	2.9	0
708	May 2015 at a glance. European Journal of Heart Failure, 2015, 17, 465-465.	2.9	0
709	Reply. Journal of the American College of Cardiology, 2015, 66, 99.	1.2	0
710	February 2016 at a glance. Focus issue on cardiac regeneration, medical treatment and cardiac devices. European Journal of Heart Failure, 2016, 18, 127-127.	2.9	0
711	March 2016 at a glance. Focus on right ventricular failure and acute heart failure. European Journal of Heart Failure, 2016, 18, 225-225.	2.9	0
712	December 2016 at a glance: cardiac metabolism, myocarditis, right ventricular function and prognostic markers. European Journal of Heart Failure, 2016, 18, 1403-1404.	2.9	0
713	A new format for the journal and a farewell. European Journal of Heart Failure, 2016, 18, 7-7.	2.9	0
714	November 2016 at a glance: the left atrium, screening for heart failure, multimodality imaging for cardiac resynchronization therapy. European Journal of Heart Failure, 2016, 18, 1305-1306.	2.9	0
715	October 2016 at a glance: treatment of heart failure. European Journal of Heart Failure, 2016, 18, 1209-1210.	2.9	0
716	May 2016 at a glance. European Journal of Heart Failure, 2016, 18, 456-456.	2.9	0
717	March 2017 at a glance: pathophysiology, imaging, biomarkers and devices. European Journal of Heart Failure, 2017, 19, 299-300.	2.9	0
718	June 2017 at a glance: biomarkers and medical treatment. European Journal of Heart Failure, 2017, 19, 699-700.	2.9	0
719	April 2017 at a glance: cardiomyopathies and clinical trials. European Journal of Heart Failure, 2017, 19, 447-448.	2.9	0
720	July 2017 at a glance: clinical assessment, biomarkers, cardiac imaging and treatment. European Journal of Heart Failure, 2017, 19, 819-820.	2.9	0

#	ARTICLE	IF	CITATIONS
721	February 2018 at a glance: heart and brain interaction, prognostic variables, and acute heart failure and post-discharge outcomes. European Journal of Heart Failure, 2018, 20, 191-192.	2.9	0
722	April 2018 at a glance: focus on prognostic variables. European Journal of Heart Failure, 2018, 20, 625-626.	2.9	0
723	March 2018 at a glance: clinical trials, co-morbidities and treatment of mitral regurgitation. European Journal of Heart Failure, 2018, 20, 411-412.	2.9	0
724	January 2018 at a glance: biomarkers, co-morbidities and mechanical circulatory support. European Journal of Heart Failure, 2018, 20, 1-2.	2.9	0
725	May 2018 at a glance: the central role of co-morbidities. European Journal of Heart Failure, 2018, 20, 833-834.	2.9	0
726	December 2018 at a glance: new imaging methods, translational cardiology and non-medical treatment. European Journal of Heart Failure, 2018, 20, 1613-1614.	2.9	0
727	October 2018 at a glance: from demographic variables to genotype-phenotype interactions. European Journal of Heart Failure, 2018, 20, 1373-1374.	2.9	0
728	July 2018 at a glance: practical guidance in acute heart failure, pathophysiology and clinical trials of medical therapy. European Journal of Heart Failure, 2018, 20, 1079-1080.	2.9	0
729	August 2019 at a glance: arrhythmogenic cardiomyopathy, biomarkers of inflammation, insulin treatment, initiation of sacubitril/valsartan, and pharmacy-based intervention to increase medication adherence. European Journal of Heart Failure, 2019, 21, 951-952.	2.9	0
730	GENETIC-AF. JACC: Heart Failure, 2019, 7, 599-601.	1.9	0
731	September 2019 at a glance: focus on devices. European Journal of Heart Failure, 2019, 21, 1049-1050.	2.9	0
732	October 2019 at a glance: epidemiology, prevention, and modes of death. European Journal of Heart Failure, 2019, 21, 1167-1168.	2.9	0
733	June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes. European Journal of Heart Failure, 2019, 21, 697-698.	2.9	0
734	May 2019 at a glance: epidemiology, drug effects on biomarkers, adverse events with LVAD. European Journal of Heart Failure, 2019, 21, 541-542.	2.9	0
735	March 2019 at a glance: epidemiology and clinical trials. European Journal of Heart Failure, 2019, 21, 259-260.	2.9	0
736	April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology. European Journal of Heart Failure, 2019, 21, 393-394.	2.9	0
737	November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment. European Journal of Heart Failure, 2019, 21, 1297-1298.	2.9	0
738	July 2020 at a glance: focus on imaging and cardiomyopathies. European Journal of Heart Failure, 2020, 22, 1057-1059.	2.9	0

#	ARTICLE	IF	CITATIONS
739	September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy. <i>European Journal of Heart Failure</i> , 2020, 22, 1493-1494.	2.9	0
740	August 2020 at a glance: focus on neurohormonal antagonists and electrolytes. <i>European Journal of Heart Failure</i> , 2020, 22, 1289-1290.	2.9	0
741	October 2020 at a glance: focus on outcomes, valve disease and patients' monitoring. <i>European Journal of Heart Failure</i> , 2020, 22, 1745-1746.	2.9	0
742	Percutaneous treatment of mitral regurgitation: looking for a final model. <i>Internal and Emergency Medicine</i> , 2020, 15, 13-15.	1.0	0
743	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. <i>Heart Failure Reviews</i> , 2021, 26, 255-262.	1.7	0
744	January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity. <i>European Journal of Heart Failure</i> , 2021, 23, 1-2.	2.9	0
745	February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 201-202.	2.9	0
746	April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 505-506.	2.9	0
747	May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 691-692.	2.9	0
748	Heart failure and pulmonary hypertension in a patient with partial anomalous pulmonary venous return and hyperthyroidism. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, e15-e17.	0.6	0
749	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. <i>European Journal of Heart Failure</i> , 2021, 23, 847-849.	2.9	0
750	July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1059-1061.	2.9	0
751	Treatment of secondary mitral regurgitation in patients with heart failure: when left ventricular ejection fraction may become not crucial. <i>EuroIntervention</i> , 2021, 17, e271-e273.	1.4	0
752	August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices. <i>European Journal of Heart Failure</i> , 2021, 23, 1247-1249.	2.9	0
753	September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment. <i>European Journal of Heart Failure</i> , 2021, 23, 1419-1421.	2.9	0
754	The Prevention of Sudden Death: New Perspectives. , 2007, , 205-213.		0
755	Anemia and heart failure: a cause of progression or only a consequence?. <i>Heart International</i> , 2007, 3, 1.	0.4	0
756	October 2021 at a glance: focus on imaging, biomarkers and comorbidities. <i>European Journal of Heart Failure</i> , 2021, 23, 1569-1571.	2.9	0

#	ARTICLE	IF	CITATIONS
757	November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices. European Journal of Heart Failure, 2021, 23, 1803-1805.	2.9	0
758	267â€fCardiac biomarkers and mortality in COVID-19 infection. European Heart Journal Supplements, 2021, 23, .	0.0	0
759	261â€fA case of metastatic myxoid liposarcoma causing cardiac tamponade. European Heart Journal Supplements, 2021, 23, .	0.0	0
760	January 2022 at a glance: time for the new <scp>ESC</scp> guidelines on heart failure. European Journal of Heart Failure, 2022, 24, 1-3.	2.9	0
761	465â€fUnmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.0	0
762	132â€fClinical characteristics and outcomes of a contemporary, real-world, single-centre cohort of patients with advanced heart failure. European Heart Journal Supplements, 2021, 23, .	0.0	0
763	December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models. European Journal of Heart Failure, 2021, 23, 1993-1994.	2.9	0
764	566â€fTransthyretin and light-chain cardiac amyloidosis: clinical characteristics, echocardiographic findings, and outcomes of a large cohort of patients in Northern Italy. European Heart Journal Supplements, 2021, 23, .	0.0	0
765	278 Cardiac involvement in a 23 years old patient with granulomatosis with polyangiitis (GPA). European Heart Journal Supplements, 2021, 23, .	0.0	0
766	April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 593-595.	2.9	0
767	May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices. European Journal of Heart Failure, 2022, 24, 735-737.	2.9	0
768	June 2022 at a glance: prevention, outcomes and treatment. European Journal of Heart Failure, 2022, 24, 913-915.	2.9	0
769	Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope. Revista Portuguesa De Cardiologia, 2022, , .	0.2	0